- Home
- ACON vs QNRX Comparison
ACON vs QNRX Comparison
Compare ACON & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- QNRX
- Stock Information
- Founded
- ACON 2008
- QNRX 2018
- Country
- ACON United States
- QNRX United States
- Employees
- ACON N/A
- QNRX N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- QNRX Medical/Dental Instruments
- Sector
- ACON Technology
- QNRX Health Care
- Exchange
- ACON Nasdaq
- QNRX Nasdaq
- Market Cap
- ACON 4.1M
- QNRX 3.3M
- IPO Year
- ACON 2022
- QNRX N/A
- Fundamental
- Price
- ACON $7.43
- QNRX $9.36
- Analyst Decision
- ACON Buy
- QNRX
- Analyst Count
- ACON 2
- QNRX 0
- Target Price
- ACON $481.00
- QNRX N/A
- AVG Volume (30 Days)
- ACON 17.6K
- QNRX 11.9K
- Earning Date
- ACON 08-13-2025
- QNRX 08-07-2025
- Dividend Yield
- ACON N/A
- QNRX N/A
- EPS Growth
- ACON N/A
- QNRX N/A
- EPS
- ACON N/A
- QNRX N/A
- Revenue
- ACON $54,601.00
- QNRX N/A
- Revenue This Year
- ACON $212.31
- QNRX N/A
- Revenue Next Year
- ACON $92.86
- QNRX N/A
- P/E Ratio
- ACON N/A
- QNRX N/A
- Revenue Growth
- ACON N/A
- QNRX N/A
- 52 Week Low
- ACON $6.20
- QNRX $5.01
- 52 Week High
- ACON $3,499.51
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- ACON 44.53
- QNRX 60.69
- Support Level
- ACON $6.79
- QNRX $8.04
- Resistance Level
- ACON $8.19
- QNRX $9.86
- Average True Range (ATR)
- ACON 0.39
- QNRX 0.48
- MACD
- ACON 0.28
- QNRX 0.04
- Stochastic Oscillator
- ACON 45.76
- QNRX 73.12
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.